Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
User-agent: * Sitemap: |
Title | GRANIX® (tbo-filgrastim) |
Description | Beneath the competitive acquisition cost is a strong clinical Learn more about GRANIX® (tbo-filgrastim) |
Keywords | N/A |
WebSite | granixhcp.com |
Host IP | 45.60.32.221 |
Location | United States |
Site | Rank |
US$13,452,805
Last updated: 2023-05-15 17:49:06
granixhcp.com has Semrush global rank of 786,773. granixhcp.com has an estimated worth of US$ 13,452,805, based on its estimated Ads revenue. granixhcp.com receives approximately 1,552,247 unique visitors each day. Its web server is located in United States, with IP address 45.60.32.221. According to SiteAdvisor, granixhcp.com is safe to visit. |
Purchase/Sale Value | US$13,452,805 |
Daily Ads Revenue | US$12,418 |
Monthly Ads Revenue | US$372,540 |
Yearly Ads Revenue | US$4,470,471 |
Daily Unique Visitors | 103,484 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
granixhcp.com. | A | 86400 | IP: 45.60.32.221 |
granixhcp.com. | A | 86400 | IP: 45.60.104.221 |
granixhcp.com. | NS | 86400 | NS Record: ns3.tevapharm.com. |
granixhcp.com. | NS | 86400 | NS Record: ns5.tevapharm.com. |
granixhcp.com. | NS | 86400 | NS Record: ns4.tevapharm.com. |
granixhcp.com. | TXT | 86400 | TXT Record: _globalsign-domain-verification=2s-jkn-gXVXLAGh2fFB6hU5LGdsacVdRdKB82ApilJ |
granixhcp.com. | TXT | 86400 | TXT Record: v=spf1 mx include:cust-spf.exacttarget.com -all |
Menu For Patients Prescribing Information Important Safety Information Menu Home Toggle Clinical Information Clinical Trials Safety Toggle Dosing and Administration Dosing Storage Administration Toggle Resources Coding Patient Savings Program GRANIX is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. TOP Beneath the competitive acquisition cost is a strong clinical core Transactional prices may vary, please contact your supplier for actual prices. A 71% reduction in duration of severe neutropenia vs placebo (1.1 days vs 3.8 days, p <0.0001) 1 Efficacy evaluated in a multinational, multicenter, randomized, controlled Phase III study of 348 chemotherapy-naïve patients with high-risk breast cancer receiving doxorubicin (60 mg/m 2 IV bolus)/docetaxel (75 mg/m 2 ) 1 See more Close |
HTTP/1.1 301 Moved Permanently Location: https://www.granixhcp.com/ Content-Length: 0 Connection: close HTTP/2 200 cache-control: no-cache pragma: no-cache content-length: 21451 content-type: text/html; charset=utf-8 expires: -1 server: Microsoft-IIS/10.0 set-cookie: ASP.NET_SessionId=tq5x02hvn5y2s2mmaj50vadv; path=/; HttpOnly; SameSite=Lax x-aspnetmvc-version: 5.2 x-aspnet-version: 4.0.30319 x-powered-by: ASP.NET arr-disable-session-affinity: true x-frame-options: DENY date: Fri, 07 Jan 2022 08:20:10 GMT set-cookie: visid_incap_2057806=Mwl6RyxLR/uNdpglDXni7Ln312EAAAAAQUIPAAAAAAD8AWMAYofMPE0yrddtWyR+; expires=Fri, 06 Jan 2023 23:03:03 GMT; HttpOnly; path=/; Domain=.granixhcp.com set-cookie: nlbi_2057806=+pOUNXGEnXvdnEnHV2/lJAAAAAC8Bo8LnH38KroHooerlrI5; path=/; Domain=.granixhcp.com set-cookie: incap_ses_281_2057806=nKmKHnMKQgw1EZZ7KlDmA7r312EAAAAAI8V4TKLRrdnOh+Q+7Nh0aA==; path=/; Domain=.granixhcp.com x-cdn: Imperva x-iinfo: 13-156885191-156885192 NNNN CT(85 173 0) RT(1641543609750 0) q(0 0 3 0) r(5 5) U6 |
Domain Name: GRANIXHCP.COM Registry Domain ID: 1793110199_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.comlaude.com Registrar URL: http://www.comlaude.com Updated Date: 2021-04-06T23:07:00Z Creation Date: 2013-04-11T20:52:36Z Registry Expiry Date: 2022-04-11T20:52:36Z Registrar: Nom-iq Ltd. dba COM LAUDE Registrar IANA ID: 470 Registrar Abuse Contact Email: abuse@comlaude.com Registrar Abuse Contact Phone: +442074218250 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS3.TEVAPHARM.COM Name Server: NS4.TEVAPHARM.COM Name Server: NS5.TEVAPHARM.COM DNSSEC: unsigned >>> Last update of whois database: 2022-01-07T08:15:49Z <<< |